ArticleDrug design, development and therapy2025
Mechanism of
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An evidence mapping study based on systematic reviews of traditional Chinese medicine for hyperuricemia.Frontiers in nutrition · 2026Pooled it
- Integrating Network Pharmacology and Metabolomics to Decipher the Mechanisms Underlying the Therapeutic Effects of Wuzhi Dripping Pills Against MASLD.Metabolites · 2026Article
- Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: Rats were administered high levels of uric acid (UA) to establish a model of hyperuricemia and subsequently treated with SMW. Then, the levels of the biochemical indicators serum uric acid (SUA), alanine aminotransferase (ALT), aspartate transaminase (AST), urea nitrogen (BUN), and creatinine (CRE) were measured, and histological analysis of stained liver and kidney tissue sections was performed. Furthermore, blood samples were collected after the animal experiment for serum untargeted metabolomics analysis via ultra-performance liquid chromatography-tandem mass spectrometry (UPLC‒MS/MS) and subsequent Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathway analysis. Results: The levels of the biochemical indicators were significantly lower in rats treated with SMW than in control rats. Additionally, metabolomics and KEGG enrichment pathway analyses indicated that central carbon metabolism, protein digestion and absorption, and amino acid biosynthesis pathways may play important regulatory roles in the SMW-mediated lowering of the SUA level in hyperuricemic rats. Conclusion: SMW effectively reduced the SUA level in hyperuricemic rat models and alleviated the renal impairment induced by hyperuricemia. The mechanism of SMW is closely associated with pathways related to central carbon metabolism in cancer, protein digestion and absorption, and amino acid biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.